HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
14
Frequently Asked Questions
What is Market Cap of HilleVax Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. HilleVax Inc market cap is $104.79M.
What is the 52-week high for HilleVax Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. HilleVax Inc 52 week high is $2.17 as of October 22, 2025.
What is the 52-week low for HilleVax Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. HilleVax Inc 52 week low is $1.34 as of October 22, 2025.
What is HilleVax Inc stock price today?
HilleVax Inc stock price today is $2.09.
What was HilleVax Inc stock price yesterday?
HilleVax Inc stock price yesterday was $2.10.
What is the PE ratio of HilleVax Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. HilleVax Inc’s P/E ratio is -1.46.
What is the Price-to-Book ratio of HilleVax Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. HilleVax Inc P/B ratio is 0.7087.
What is the 50-day moving average of HilleVax Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. HilleVax Inc 50-day moving average is $2.09.
